Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Deuterated forms of acetaminophen and uses thereof

a technology of acetaminophen and deuterated forms, which is applied in the field of deuterated forms of acetaminophen and, can solve the problems of acetaminophen overdose remains a significant problem, the safety of acetaminophen is not known, and scientists have been unsuccessful in developing and commercializing a safer, improved form of acetaminophen, so as to avoid or reduce the incidence of life-threatening side effects, differen

Pending Publication Date: 2022-10-06
LENNHAM PHARMA INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a new invention of medication that can help treat pain, fever, and other ailments without causing liver injury or other side effects. It does this by using a safe and effective form of a drug called deuterated acetaminophen, which helps reduce the production of a toxic chemical in the body. This new medication can be given to humans and other mammals.

Problems solved by technology

Despite its widespread use, acetaminophen has been known for years to cause liver injury.
Notwithstanding the FDA's actions, acetaminophen overdose remains a significant problem, as it is the leading cause of acute liver failure in the United States.
Despite being on the market for more than sixty (60) years, scientists have been unsuccessful in developing and commercializing a safer, improved form of acetaminophen.
Unfortunately, alternatives to acetaminophen, such as NSAIDs and opioids, come with different, but serious, and in many cases life threatening, risks.
For example, NSAIDs, such as ibuprofen, today carry a “black box” warning of (a) an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, and (b) an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, both of which may be fatal.
Opioids, on the other hand, are widely known to lead to addiction, abuse, and misuse, which can result in overdose and death.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Deuterated forms of acetaminophen and uses thereof
  • Deuterated forms of acetaminophen and uses thereof
  • Deuterated forms of acetaminophen and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0059]A study was performed to assess whether a deuterated form of acetaminophen would reduce the production of the reactive metabolite NAPQI when compared to a non-deuterated form of acetaminophen. In the study, acetaminophen and acetaminophen-d4 were incubated with human liver microsomes, with glutathione (GSH) as a trapping agent. The collected samples were analyzed by UPLC / HR-MS to screen and identify the possibly forming trapped reactive metabolites.[0060]Sample type: Pooled liver microsomes[0061]Species: Human (pooled)[0062]Time points: 0, 15, 30, 60, 90 minutes with and without cofactors (all with 2 mM GSH)+60 minutes blank[0063]Concentration: 10 μM[0064]Cofactors: NADPH (2 mM), UDPGA (1 mM), alamethicin 15 μg / ml[0065]Protein content: 1 mg / ml[0066]Replicates: 3[0067]Buffer: phosphate buffer pH 7.4+MgCl2 (2 mM)[0068]Incubation volume: 300 μl; Sampling volume: 40 μl; Quenching: 2-fold volume of 75% acetonitrile[0069]Stock solvent: 50% DMSO (spiking 1 / 100 to incubation)[0070]Pos...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
natural abundanceaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating various diseases and conditions with a reduced risk of liver injury or other side effects associated with non-deuterated forms of acetaminophen.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]The present application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62 / 861,073, filed on Jun. 13, 2019, and U.S. Provisional Application No. 62 / 857,226, filed on Jun. 4, 2019, the entire contents of which are herein incorporated by reference.BACKGROUND OF THE INVENTION[0002]Acetaminophen (also known as paracetamol) was approved by the FDA in 1951 and is one of the most widely used drugs in the United States. Today, acetaminophen is found in hundreds of over-the-counter (OTC) and prescription medicines, including in Tylenol-brand products, as an intravenous formulation (OFIRMEV), and in prescription combination drug products such as Vicodin and Percocet.[0003]The chemical structure of acetaminophen, N-(4-Hydroxyphenyl)acetamide, is as follows:[0004]Acetaminophen is a pain reliever and fever reducer that is used to treat many conditions including headaches, muscle aches, arthritis, backache, toothaches, cold...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/167A61P29/00
CPCA61K31/167A61P29/00A61K31/165A61P1/16A61K31/522A61K45/06
Inventor SIPPY, BRADFORD C.
Owner LENNHAM PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products